Literature DB >> 27410519

HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?

Amer A Beg1, Jhanelle E Gray2.   

Abstract

Entities:  

Keywords:  PD-1; T cells; T-cell chemokines; clinical trial; epigenetic agents; histone deacetylase inhibitors; immunotherapy; lung cancer; romidepsin; vorinostat

Mesh：

Substances：

Year:  2016        PMID： 27410519     DOI： 10.2217/epi-2016-0066

Source DB:  PubMed          Journal:  Epigenomics        ISSN： 1750-192X            Impact factor:   4.778


× No keyword cloud information.
  11 in total

Review 1.  Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells.

Authors:  Laurence Booth; Jane L Roberts; John Kirkwood; Andrew Poklepovic; Paul Dent
Journal:  Adv Cancer Res       Date:  2018-01-03       Impact factor: 6.242

2.  Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.

Authors:  Ashley Orillion; Ayumi Hashimoto; Nur Damayanti; Li Shen; Remi Adelaiye-Ogala; Sreevani Arisa; Sreenivasulu Chintala; Peter Ordentlich; Chingai Kao; Bennett Elzey; Dmitry Gabrilovich; Roberto Pili
Journal:  Clin Cancer Res       Date:  2017-07-11       Impact factor: 12.531

3.  [pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells.

Authors:  Laurence Booth; Jane L Roberts; Andrew Poklepovic; Paul Dent
Journal:  Cancer Biol Ther       Date:  2017-09-02       Impact factor: 4.742

4.  Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer.

Authors:  Jhanelle E Gray; Amer A Beg; Andreas Saltos; Tawee Tanvetyanon; Eric B Haura; Ben Creelan; Scott J Antonia; Michael Shafique; Hong Zheng; Wenjie Dai; James J Saller; Zhihua Chen; Nishan Tchekmedyian; Kristen Goas; Ram Thapa; Theresa A Boyle; Dung-Tsa Chen
Journal:  Clin Cancer Res       Date:  2019-08-13       Impact factor: 12.531

Review 5.  Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas.

Authors:  Alexander Neuwelt; Taha Al-Juhaishi; Eduardo Davila; Bradley Haverkos
Journal:  Blood Adv       Date:  2020-09-08

Review 6.  Insights into the therapeutic potential of histone deacetylase inhibitor/immunotherapy combination regimens in solid tumors.

Authors:  Nada K Sedky; Alyaa A Hamdan; Salma Emad; Aya L Allam; Mohamed Ali; Mai F Tolba
Journal:  Clin Transl Oncol       Date:  2022-01-23       Impact factor: 3.405

7.  HDAC inhibitors enhance the immunotherapy response of melanoma cells.

Authors:  Laurence Booth; Jane L Roberts; Andrew Poklepovic; John Kirkwood; Paul Dent
Journal:  Oncotarget       Date:  2017-05-17

Review 8.  Cancer Stem Cells: Devil or Savior-Looking behind the Scenes of Immunotherapy Failure.

Authors:  Lorenzo Castagnoli; Francesca De Santis; Tatiana Volpari; Claudio Vernieri; Elda Tagliabue; Massimo Di Nicola; Serenella M Pupa
Journal:  Cells       Date:  2020-02-27       Impact factor: 6.600

Review 9.  Lessons learned from the blockade of immune checkpoints in cancer immunotherapy.

Authors:  Xiaolei Li; Changshun Shao; Yufang Shi; Weidong Han
Journal:  J Hematol Oncol       Date:  2018-02-27       Impact factor: 17.388

10.  SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.

Authors:  Ruiyan Wu; Caiqin Wang; Zhiming Li; Jian Xiao; Chunyan Li; Xuemin Wang; Pengfei Kong; Jianghua Cao; Fuxue Huang; Zhiling Li; Yun Huang; Yuhong Chen; Xuan Li; Dong Yang; Hailiang Zhang; Jia Mai; Gongkan Feng; Rong Deng; Xiaofeng Zhu
Journal:  J Immunother Cancer       Date:  2020-11       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.